carbostyril has been researched along with Inflammatory Breast Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ | 1 |
1 trial(s) available for carbostyril and Inflammatory Breast Neoplasms
Article | Year |
---|---|
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2013 |